Tetrahydropyrimidin-4(1H)-one → HCID 58529489, Verbindung
Reaktionsgleichung
[CH2:1]([N:8]1[CH:16]=[C:15]2[C:10]([CH:11]=[C:12]([C:17]3[CH:18]=[C:19]([C:27]4[CH:32]=[CH:31][C:30]([CH2:33]Br)=[CH:29][CH:28]=4)[N:20]4[C:25]=3[C:24]([NH2:26])=[N:23][CH:22]=[N:21]4)[CH:13]=[CH:14]2)=[N:9]1)[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[NH:35]1[CH2:40][CH2:39][C:38](=[O:41])[NH:37][CH2:36]1>>[NH2:26][C:24]1[C:25]2=[C:17]([C:12]3[CH:13]=[CH:14][C:15]4[C:10]([CH:11]=3)=[N:9][N:8]([CH2:1][C:2]3[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=3)[CH:16]=4)[CH:18]=[C:19]([C:27]3[CH:32]=[CH:31][C:30]([CH2:33][N:35]4[CH2:40][CH2:39][C:38](=[O:41])[NH:37][CH2:36]4)=[CH:29][CH:28]=3)[N:20]2[N:21]=[CH:22][N:23]=1Komponenten
3
Versuchsvorschrift
Using a procedure similar to that of Example 282, step 2, with 5-(2-benzyl-2H-indazol-6-yl)-7-(4-bromomethyl-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-ylamine and tetrahydro-pyrimidin-4-one as starting materials, 14 mg (4.5%) of the desired product was isolated. 1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1 H), 8.05 (d, 2 H), 8.0 (s, 1 H), 7.90 (d, 1 H), 7.70 (s, 1 H), 7.60-7.40 (m, 7 H), 7.25 (d, 1 H), 7.20 (s, 1 H), 5.70 (s, 2 H), 3.60 (s, 2 H), 3.20 (t, 2 H), 2.95 (s, 2 H), 2.60 (t, 2 H); ES-MS m/z 529.29 [M+H]+, HPLC RT (min) 2.24.